Insoluble Particulate Matter Testing Under the Chinese Pharmacopoeia (ChP 0903): Methods, Limits, an

Insoluble particulate matter testing, specified in the Chinese Pharmacopoeia (ChP) 2020 Edition General Chapter 0903, is a mandatory quality control test for intravenous injections and sterile powders for injection. This article explains the regulatory basis of the test, applicable sample types, particle count limits, the light obscuration and microscopic counting methods, and practical considerations for pharmaceutical laboratories seeking compliance.

Technical Overview

Insoluble particulate matter testing is a pharmacopoeial procedure designed to detect and quantify sub-visible particles in parenteral drug products. In the Chinese Pharmacopoeia (ChP) 2020 Edition, Volume IV, the test is codified in General Chapter 0903, which applies to intravenous injections, sterile powders for injection, and, where specified in individual monographs, other parenteral dosage forms.

Sub-visible particles, generally understood as particles too small to be reliably detected by visual inspection, may originate from raw materials, manufacturing equipment, cleanroom environments, packaging components such as rubber closures and glass vials, or from product degradation and precipitation during storage. Because the inner diameter of human capillaries is only on the order of several micrometers, particles of 10 micrometers or larger can obstruct the microvasculature and are associated with clinical risks including phlebitis, granuloma formation, thrombosis, and pulmonary embolism. For this reason, the pharmacopoeia regulates particle loads at two principal thresholds: 10 micrometers and 25 micrometers.

The ChP requirements are broadly harmonized with the corresponding chapters of the United States Pharmacopeia (USP General Chapter 788), the European Pharmacopoeia (Ph. Eur. 2.9.7), and the Japanese Pharmacopoeia, while retaining certain distinctive procedural provisions that laboratories must observe when testing products for the Chinese market.

Testing Samples

Large-Volume Intravenous Injections (Labeled Volume of 100 mL or More)

This category includes infusion products such as sodium chloride injection, glucose injection, electrolyte replacement solutions, and large-volume parenterals supplied in flexible bags or glass bottles. Because a large volume is administered to the patient, the acceptance limits are expressed as particle counts per milliliter, providing a concentration-based measure of particle burden.

Small-Volume Intravenous Injections (Labeled Volume Below 100 mL)

This category covers ampoules and vials with a labeled volume of less than 100 mL, including both chemical drug products and traditional Chinese medicine injections intended for intravenous use. Since the entire container content is typically administered or diluted, acceptance limits are expressed as total particle counts per container.

Sterile Powders for Injection

Sterile powders for intravenous administration, such as antibiotic powders in vials, are first reconstituted with particle test water or with the solvent specified in the product labeling, following the labeled dilution volume. The resulting solution is then tested using the same procedure as for liquid injections, with limits expressed per container.

Testing Items

The core measured parameters of the test are as follows:

• The number of particles equal to or larger than 10 micrometers, reported per milliliter or per container depending on product type.
• The number of particles equal to or larger than 25 micrometers, reported per milliliter or per container depending on product type.
• Instrument suitability verification, including calibration of the particle counter with certified standard particles of known size, typically 10 micrometer and 25 micrometer polystyrene latex spheres traceable to a national metrology institute.
• Background control of the particle test water, which must be verified to contain no more than 10 particles of 10 micrometers or larger per milliliter and no more than 2 particles of 25 micrometers or larger per milliliter.

Testing Methods

Method 1: Light Obscuration Particle Counting

Light obscuration is the preferred and default method. The sample is drawn through a narrow, illuminated sensing zone; each particle intercepts a portion of the light beam and casts a shadow on a photodetector. The amplitude of the resulting electrical pulse is proportional to the projected area of the particle and is converted to an equivalent circular diameter, allowing particles to be counted within defined size channels.

In practice, the instrument is installed in a clean environment to minimize background contamination. The sample container is gently inverted approximately twenty times to homogenize the content without introducing air bubbles. Consecutive readings of five milliliters are taken; the first reading is discarded to rinse the sampling path, and the average of the subsequent readings is calculated as the result. Products that foam, are highly viscous, or generate bubbles may yield false counts and are better suited to Method 2.

• For intravenous injections with a labeled volume of 100 mL or more: not more than 25 particles of 10 micrometers or larger per milliliter, and not more than 3 particles of 25 micrometers or larger per milliliter.
• For intravenous injections with a labeled volume below 100 mL: not more than 6000 particles of 10 micrometers or larger per container, and not more than 600 particles of 25 micrometers or larger per container.
• For sterile powders for intravenous injection after reconstitution: not more than 6000 particles of 10 micrometers or larger per container, and not more than 600 particles of 25 micrometers or larger per container.

Method 2: Microscopic Particle Counting

The microscopic method is applied when the light obscuration method is unsuitable, for example for lipid emulsions, suspensions, highly viscous solutions, dark-colored products, or liquids that foam readily. It is also commonly used as the arbitration method when test results are disputed.

A measured volume of the sample is filtered through a gridded membrane filter with a pore size of 0.45 micrometers or finer, and the filtration apparatus and container walls are rinsed with particle test water. The membrane is then examined under a microscope, typically at a total magnification of 100 times, using an ocular micrometer calibrated against a certified stage micrometer. Particles of 10 micrometers or larger and 25 micrometers or larger are counted within defined grid areas and the counts are extrapolated to the effective filtration area, corrected for a blank determination, and reported per milliliter or per container.

• For intravenous injections with a labeled volume of 100 mL or more: not more than 12 particles of 10 micrometers or larger per milliliter, and not more than 2 particles of 25 micrometers or larger per milliliter.
• For intravenous injections with a labeled volume below 100 mL and for sterile powders for injection: not more than 3000 particles of 10 micrometers or larger per container, and not more than 300 particles of 25 micrometers or larger per container.

Applications

Insoluble particulate matter testing supports multiple quality and regulatory functions across the product lifecycle:

• Batch release testing of intravenous injections and sterile powders for injection prior to market distribution.
• Long-term and accelerated stability studies, where particle growth indicates degradation, crystallization, or container interaction.
• Packaging compatibility studies, including evaluation of glass delamination, rubber stopper coring, and silicone oil migration from syringes and cartridges.
• Root cause investigation of visible and sub-visible particle complaints, supporting corrective and preventive action programs.
• Comparative testing of infusion sets, in-line filters, and dilution procedures to assess particle burden introduced during clinical preparation.
• Regulatory submissions for export markets, where testing aligned with ChP, USP, and Ph. Eur. requirements demonstrates global compliance.

FAQ

Why are the particle size thresholds set at 10 and 25 micrometers?

Human capillaries have an internal diameter of only several micrometers, roughly comparable to the size of a red blood cell. Particles of 10 micrometers or larger can lodge in small vessels and provoke inflammatory reactions, while particles of 25 micrometers or larger carry a substantially higher risk of vascular occlusion. The two thresholds therefore provide both a sensitive early warning and a strict safety limit.

When should the microscopic method be used instead of light obscuration?

The microscopic method should be used when the product matrix interferes with light obscuration measurement, such as emulsions and suspensions whose dispersed droplets generate excessive sensor counts, as well as viscous, foaming, or intensely colored solutions. It is also the recognized arbitration method when light obscuration results are contested.

Are ChP limits the same as USP and Ph. Eur. limits?

The numerical limits for the light obscuration method are closely harmonized among the major pharmacopoeias. However, procedural details such as sample preparation, instrument calibration requirements, and the handling of specific dosage forms differ slightly, so laboratories should execute the test exactly as written in the applicable pharmacopoeial chapter for the target market.

What are the most common sources of insoluble particles?

Typical sources include rubber closure fragments from needle penetration or vial sealing, glass flakes from delamination, environmental dust from inadequate cleanroom control, extruded material from tubing and filters, silicone oil droplets from prefilled syringes, drug crystallization or precipitation, and incompatibility reactions occurring during dilution or co-infusion.

Does the test apply to all injectable products?

No. General Chapter 0903 specifically targets products administered by the intravenous route, namely intravenous injections and sterile powders for intravenous injection. Products for other routes of administration are exempt unless the individual monograph or the marketing authorization specifies the test.

How can laboratories reduce background contamination during testing?

Key measures include performing the test in a laminar flow or otherwise clean environment, filtering all water and solvents through fine membrane filters and verifying the background count, using low-particulate glassware rinsed with filtered water, minimizing operator movement, and qualifying consumables such as membranes and sampling needles for intrinsic particle contribution.